Jorge Armando Quiroz Sells 40,150 Shares of Solid Biosciences Inc (SLDB) Stock

Solid Biosciences Inc (NASDAQ:SLDB) insider Jorge Armando Quiroz sold 40,150 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $31.21, for a total transaction of $1,253,081.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ:SLDB traded down $1.86 during mid-day trading on Tuesday, hitting $28.49. The stock had a trading volume of 201,766 shares, compared to its average volume of 294,136. The company has a market cap of $1.10 billion and a PE ratio of -9.89. Solid Biosciences Inc has a 12-month low of $6.83 and a 12-month high of $54.84.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Tuesday, November 13th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. As a group, sell-side analysts predict that Solid Biosciences Inc will post -2.21 EPS for the current year.

SLDB has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Solid Biosciences from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research report on Wednesday, October 17th. Credit Suisse Group initiated coverage on shares of Solid Biosciences in a research report on Thursday, September 6th. They issued a “neutral” rating and a $38.00 price target for the company. Finally, Citigroup upped their price target on shares of Solid Biosciences from $25.00 to $31.00 and gave the company a “sell” rating in a research report on Monday. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. Solid Biosciences has an average rating of “Hold” and an average target price of $42.56.

Several large investors have recently modified their holdings of the stock. American International Group Inc. lifted its position in shares of Solid Biosciences by 36.3% in the 3rd quarter. American International Group Inc. now owns 8,085 shares of the company’s stock valued at $381,000 after acquiring an additional 2,154 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Solid Biosciences by 12.5% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 22,524 shares of the company’s stock valued at $1,063,000 after acquiring an additional 2,504 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Solid Biosciences by 7.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 38,011 shares of the company’s stock valued at $1,355,000 after acquiring an additional 2,658 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Solid Biosciences by 14.3% in the 3rd quarter. Teachers Advisors LLC now owns 21,653 shares of the company’s stock valued at $1,022,000 after acquiring an additional 2,710 shares in the last quarter. Finally, Partner Investment Management L.P. increased its stake in Solid Biosciences by 75.4% in the 3rd quarter. Partner Investment Management L.P. now owns 6,604 shares of the company’s stock valued at $312,000 after buying an additional 2,838 shares during the period. Institutional investors and hedge funds own 63.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Jorge Armando Quiroz Sells 40,150 Shares of Solid Biosciences Inc (SLDB) Stock” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.com-unik.info/2018/12/04/jorge-armando-quiroz-sells-40150-shares-of-solid-biosciences-inc-sldb-stock.html.

Solid Biosciences Company Profile

Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.

Recommended Story: Dividend Stocks – Are They Right For You?

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit